Editorial: Immunotherapy for acute myeloid leukaemia.
D000912:Antibodies, Neoplasm / Q000302:isolation & purification; D000917:Antibody Formation; D000936:Antigen-Antibody Complex; D000951:Antigens, Neoplasm / Q000302:isolation & purification; D001500:BCG Vaccine / Q000008:administration & dosage; D002471:Cell Transformation, Neoplastic; D003561:Cytarabine / Q000627:therapeutic use; D003630:Daunorubicin / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006801:Humans; D007153:Immunologic Deficiency Syndromes / Q000150:complications; D007167:Immunotherapy; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000209:etiology / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D012075:Remission, Spontaneous; D013866:Thioguanine / Q000627:therapeutic use
D000912:Antibodies, Neoplasm; D000936:Antigen-Antibody Complex; D000951:Antigens, Neoplasm; D001500:BCG Vaccine; D003561:Cytarabine; D013866:Thioguanine; D003630:Daunorubicin